COMMUNIQUÉS West-GlobeNewswire

Curia Invests $4 Million to Enhance Sterile API Manufacturing
27/10/2025
ALBANY, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the completion of a $4 million investment to upgrade its [...]
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
27/10/2025
Orchestra BioMed’s Virtue ® Sirolimus AngioInfusion TM Balloon (“Virtue SAB”) is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release sirolimus (“ [...]
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
27/10/2025
Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHS Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) [...]
Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement
27/10/2025
Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
Prenetics Announces $48.0 Million Equity Offering to Fuel IM8’s Global Expansion and Bitcoin Treasury Strategy
27/10/2025
CHARLOTTE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“ Prenetics ” or the “ Company ”), a leading health sciences company, today announced the successful pricing of a best efforts [...]
A New Era for Dermatology PAs and NPs Begins with PANP360
27/10/2025
The one-of-a-kind platform unites peer connection, clinical learning, and purpose under one home Plano, Texas, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Dermsquared is proud to announce the launch of PANP360 , a reimagined hub [...]
Rakovina Therapeutics Showcases Potent AI-Developed ATR Inhibitors with CNS Penetrance at AACR-NCI-EORTC International Conference
27/10/2025
VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) is pleased to announce the successful presentation of new data at the AACR- [...]
NHS-licensed healthcare platform Evaro partners with period tracking app Clue in UK-first integration
27/10/2025
Partnership bridges the gap between period tracking and contraception access as nearly half of UK women face barriers to contraception care LONDON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Evaro, the NHS-licensed embedded [...]
Levicept Presents New Data Suggesting a Novel Neurotrophin-3 Inhibitor, LEVI-04, May Modify Disease and Improve Symptoms in Osteoarthritis
27/10/2025
Clinical and Pharmacology Data Presented at ACR Convergence 2025 In a Phase II trial, LEVI-04 demonstrated a significant, dose-dependent reduction in bone marrow lesions (BML) compared with placebo in patients with [...]
Amphista Therapeutics’ successful degradation of a key cancer target, BRD9, via a novel mechanism with DCAF16 E3 ligase published in Nature Communications
27/10/2025
The publication reports the highly selective, DCAF16 E3 enabled degradation of BRD9 in vivo using Amphista’s proprietary, next generation Targeted Glue™ medicinal chemistry technology Amphista’s scientists prospectively [...]
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
27/10/2025
NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglutide Class-leading [...]
Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET
27/10/2025
WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
27/10/2025
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical studies conducted in [...]
Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
27/10/2025
SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein [...]
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study
27/10/2025
- All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company’s prior studies - Primary interim analysis endpoint, [...]
Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence
27/10/2025
Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Treatment was well tolerated with minimal effects on weight or blood pressure and discontinuation rate [...]
World's First Multi-Omics LLM, Promising to Decode the Language of Human Biology Showcasing in Global Health Exhibition, Riyadh
27/10/2025
PanOmiQ’s foundational model trained on multi-Omics data breakthrough FPGA-powered deployment addresses data sovereignty challenge, ultrafast AI-driven multi-omics analysis on premises, redefining speed and accuracy in [...]
Citryll Presents Positive Data from Phase I Study of CIT-013 in Rheumatoid Arthritis at ACR Convergence 2025
27/10/2025
CITRYLL PRESENTS POSITIVE DATA FROM PHASE I STUDY OF CIT-013 IN RHEUMATOID ARTHRITIS AT ACR CONVERGENCE 2025 Phase I trial data in rheumatoid arthritis patients demonstrates favorable safety, encouraging clinical [...]
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
27/10/2025
ALAMEDA, Calif., Oct. 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today [...]

Pages